Mark A. Lewis, MD, explains when unexpected disease behavior in neuroendocrine tumors should prompt a specialist referral and how patients can still be treated close to home.
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.